Plain-English translation of NCT06143514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how much BRIUMVI™ — a medication used to treat relapsing forms of multiple sclerosis — may pass into breast milk. This study will collect milk samples from women who are already taking this medication for their MS and are actively breastfeeding. The goal is to give mothers and doctors clear information about whether it's safe to breastfeed while using this treatment.
Many women with multiple sclerosis want to breastfeed their babies, but they need to know whether medications used to control their disease could affect their infants through breast milk. This study fills that knowledge gap by measuring exactly how much of the medication appears in milk, helping doctors and mothers make informed decisions.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll collect breast milk samples over a 24-hour period following one of your regular medication doses. You'll pump exclusively during this time to provide milk samples that researchers will test to measure medication concentration. Your baby's health will be monitored to ensure they remain safe throughout the study period, which lasts only as long as you continue breastfeeding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States